17α-Ethinyl estradiol-3-sulfate increases survival and hemodynamic functioning in a large animal model of combined traumatic brain injury and hemorrhagic shock: a randomized control trial
Abstract
Traumatic brain injury (TBI) and severe blood loss resulting in hemorrhagic shock (HS) represent leading causes of trauma-induced mortality, especially when co-occurring in pre-hospital settings where standard therapies are not readily available. The primary objective of this study was to determine if 17α-ethinyl estradiol-3-sulfate (EE-3-SO4) increases survival, promotes more rapid cardiovascular recovery, or confers neuroprotection relative to Placebo following TBI + HS.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 16, 2021
- Source ID
- 10.1186/s13054-021-03844-7
Entities
People
- Amy L. Lloyd
- Andrew B. Dodd
- Andrew P. Gigliotti
- Andrew R Mayer
- Carissa J. Mehos
- Chen Lai
- Cidney R. Robertson-benta
- David D. Stephenson
- Erik B. Erhardt
- Irshad H. Chaudry
- Jessica M. Gill
- Josef M. Ling
- Julie G. Rannou-latella
- Meghan S. Vermillion
- Rachel E. Kinsler
- Rebecca J. Dodd
- Sharvani Pabbathi Reddy
- Veronik Sicard
- Vivian A. Guedes
Organizations
- National Institute of General Medical Sciences
- United States Department of Defense